Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
13,258
Total Claims
$10.3M
Drug Cost
607
Beneficiaries
$17K
Cost/Patient
Risk Score Breakdown 33/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+45%
Opioid rate vs peers
3.3% vs 2.2% avg
+1098%
Cost per patient vs peers
$17K vs $1,411 avg
+173%
Brand preference vs peers
29.1% vs 10.6% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Cost per patient is 1098% above the specialty average. Extreme cost outliers may indicate prescribing of unnecessarily expensive brand-name drugs or inappropriate drug utilization.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
3.3%
Opioid Rate
431
Opioid Claims
$55K
Opioid Cost
33.2%
Long-Acting Rate
Brand vs Generic
Brand: 3,837 claims · $9.7M
Generic: 9,369 claims · $543K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Bictegrav/Emtricit/Tenofov Ala | 332 | $1.6M |
| Somatropin | 48 | $883K |
| Dolutegravir Sodium | 282 | $803K |
| Abacavir/Dolutegravir/Lamivudi | 208 | $788K |
| Emtricitab/Rilpiviri/Tenof Ala | 198 | $783K |
| Emtricitabine/Tenofov Alafenam | 267 | $641K |
| Elviteg/Cob/Emtri/Tenof Alafen | 90 | $396K |
| Dolutegravir Sodium/Lamivudine | 106 | $365K |
| Dolutegravir/Rilpivirine | 103 | $358K |
| Darunavir/Cob/Emtri/Tenof Alaf | 70 | $351K |
| Raltegravir Potassium | 160 | $323K |
| Tesamorelin Acetate | 32 | $250K |
| Doravirine | 101 | $182K |
| Darunavir | 80 | $172K |
| Lipase/Protease/Amylase | 62 | $157K |
Prescribing Profile
Patient Profile
71
Avg Age
14%
Female
1.33
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About